Equities

SDS Optic SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
SDS:WSE

SDS Optic SA

Actions
  • Price (PLN)7.80
  • Today's Change-0.20 / -2.50%
  • Shares traded15.16k
  • 1 Year change-11.36%
  • Beta0.3495
Data delayed at least 15 minutes, as of Feb 06 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

SDS Optic SA is a Poland-based company engaged primarily in medical research. The Company’s primary research activity relates to the oncology sector. The Firm wishes to develop a method for early breast cancer diagnosis. The current method of diagnosis relies on biopsy and histopathology. The purpose of the tests is to identify cancer markers. The Company tries to implement InProbe method, which is faster and more accurate- the method should be able to provide results within 20 minutes. The Company is also engaged in research regarding different kinds of diseases such as fungal diseases. The Company cooperates with specialists from different fields such as biology, medicine, technology, and sciences related to medicine.

  • Revenue in PLN (TTM)7.44m
  • Net income in PLN-483.71k
  • Incorporated2019
  • Employees41.00
  • Location
    SDS Optic SACentrum ECOTECH-COMPLEXBlock A, ul. Gleboka 39LUBLIN 20-612PolandPOL
  • Phone+48 815019463
  • Websitehttps://sdsoptic.pl/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Stem Cells Spin SA115.74k-510.92k16.53m1.00--2.5312.67142.86-0.0124-0.01240.00280.15810.01030.0083.43115,740.00-4.52-1.02-4.57-1.0595.9193.18-441.44-50.721.03-133.660.0262---87.06-37.78-237.07------
Medicofarma Biotech SA281.45k-3.06m35.48m24.00--7.46--126.08-0.0450-0.04500.00410.070.019966.640.746911,727.08-21.55-14.96-31.48-18.5938.8036.02-1,085.51-64.020.821-11.710.00--63.14-17.3933.11------
GENOMED SA27.49m3.27m37.79m53.0011.553.049.371.372.482.4820.819.422.215.1712.68509,166.1026.317.5128.798.8165.2462.3311.903.847.51--0.00--2.343.1819.321.9815.97--
Sds Optic SA7.44m-483.71k50.40m41.00--51.32228.836.77-0.0815-0.08151.250.15590.54975.12125.84181,486.60-4.01-32.89-4.24-41.3598.1949.49-7.29-136.622.500.62780.00--40.53301.05-45.06--57.27--
Sygnis SA7.73m-6.34m56.50m12.00--1.76--7.31-0.2499-0.24990.33091.170.1166-0.16896.14218,427.70-9.03-8.61-15.00-12.10108.4959.85-77.44-39.140.6697-0.00660.13---52.2926.88-47.44---9.50--
Read Gene SA15.19m-887.46k71.21m11.00--26.58--4.69-0.0536-0.05361.170.22731.0839.776.30---6.32-2.40-6.88-2.7492.6390.21-5.84-4.306.31-0.6960.00--30.3826.3817.49------
Genomtec SA15.00k-11.01m72.31m----6.99--4,820.68-0.7485-0.74850.0010.68690.0009--0.0143---65.47-89.96-82.11-113.38-54,120.00-4,379.72-73,393.34-17,225.072.82-39.820.1409--0.00-63.42-24.35---34.54--
Hyenergy SA3.29m169.85k77.91m27.00--3.95318.9023.69-0.0936-0.09360.16540.58780.18210.12590.7741--0.94032.391.283.3599.7077.465.163.111.301.170.00--192.8319.47100.30---45.79--
Nanogroup SA-6.90k-6.93m83.88m----7.19-----0.1844-0.1844-0.00020.3553-0.00032.64-----30.59-29.50-51.55-33.80--66.72---2,258.260.9785-464.180.00--3.96-64.0934.50--3.07--
Urteste SA0.00-5.47m87.29m34.00--3.73-----3.88-3.880.0015.350.00-------15.56-29.65-18.99-31.35---45,933.33---623,333.30----0.0128------35.00--197.79--
Poltreg SA0.00-24.56m122.65m33.00--2.48-----5.27-5.270.0010.610.0016.45--0.00-25.87-9.02-29.62-10.18---659.36---854.232.65--0.1365---74.98-6.89-38.06--83.47--
Mabion SA14.81m-59.30m132.37m204.00--1.89--8.94-3.67-3.670.91644.330.09888.1027.2572,602.94-39.560.5366-54.811.06-178.5558.34-400.370.96430.2276--0.04---54.50---115.35--6.00--
Molecure SA5.11m-24.42m140.93m71.00--1.58--27.57-1.20-1.200.24934.340.0553--7.0150,119.41-26.42-3.15-27.53-3.3051.4893.34-477.67-15.45----0.0588---40.47278.20-10.27--12.49--
Data as of Feb 06 2026. Currency figures normalised to SDS Optic SA's reporting currency: Polish New Zloty PLN

Institutional shareholders

2.49%Per cent of shares held by top holders
HolderShares% Held
Norges Bank Investment Managementas of 30 Jun 2025157.00k2.49%
Data from 30 Jun 2025 - 30 Jun 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.